[EN] CBI DERIVATIVES SUBJECT TO REDUCTIVE ACTIVATION<br/>[FR] DÉRIVÉS CBI SUJETS À UNE ACTIVATION RÉDUCTRICE
申请人:SCRIPPS RESEARCH INST
公开号:WO2009064908A1
公开(公告)日:2009-05-22
A unique class of N-acyl O-amino phenol prodrugs of CBI-TMI and CBI-indole2 were synthesized and shown to be prodrugs, subject to reductive activation by nucleophilic cleavage of a weak N-O bond, effectively releasing the free drug in functional cellular assays for cytotoxic activity approaching or matching the activity of the free drug, yet remain essentially stable to ex vivo DNA alkylation conditions. Most impressively, assessment of the in vivo antitumor activity of a representative O- (acylamino) prodrug, 8, indicate that they approach the potency and exceed the efficacy of the free drug itself (CBI-indole2), indicating that the inactive prodrugs not only effectively release the free drug in vivo, but that they offer additional advantages related to a controlled or targeted release in vivo.
一种独特的N-酰基O-氨基酚前药类CBI-TMI和CBI-indole2已合成,并证明它们是前药,受到亲核断裂弱N-O键的还原激活,有效地释放自由药物,在功能细胞活性测定中表现出接近或匹配自由药物活性的细胞毒活性,同时在离体DNA烷基化条件下基本稳定。最令人印象深刻的是,评估代表性O-(酰胺基)前药8的体内抗肿瘤活性表明,它们接近或超过了自由药物本身(CBI-indole2)的效力,表明这些无活性前药不仅在体内有效释放自由药物,而且在体内提供了与控制或靶向释放相关的额外优势。